rusfertide

**Rusfertide** is a synthetic, first-in-class hepcidin-mimetic peptide that binds the iron exporter ferroportin and promotes its internalization and degradation, restricting iron export into plasma and reducing iron availability for erythropoiesis. It is administered by once-weekly subcutaneous injection and is approved in the United States as **Mimrylo** for treatment of erythrocytosis in adults with polycythemia vera. Rusfertide was discovered by Protagonist Therapeutics and is partnered with Takeda. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder))

Brand names

Mimrylo

Other names

rusfertide acetate